Eli Lilly (LLY)
Guggenheim Managing Director Seamus Fernandez evaluates Eli Lilly's market position, noting a strong patient and physician preference for its weight loss drugs, Mounjaro and Zepbound. He further analyzes the company's accelerating pipeline and robust patent estate, which contribute to its leadership in the GLP-1 market.
* Does not constitute investment advice